Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

atugen AG Discovers Novel Cancer Target

21.01.2003


atugen AG, a private company focused on the elucidation of disease pathways, today announced the identification of a novel cancer target that appears to play an important role in tumor growth and metastasis. atugen’s research group has demonstrated that inhibition of the novel target, Atu027, which has homology to protein kinases, results in blockage of tumor growth of human prostate carcinoma cells in orthotopic mouse models. atugen has demonstrated that human prostate tumor cells engineered to express siRNA molecules against the kinase shows significant reduction or even complete lack of secondary tumors indicating a role of the kinase in tumor progression and metastasis.



The novel target, Atu027, is the result of the company’s internal research program on the phosphatidylinositol 3-OH kinase (PI 3-K) pathway. The approach was presented at the Cold Spring Harbor Laboratory’s Tumor Suppressor August 2002 Meeting in Cold Spring Harbor, NY. PI 3-K is a central signal transduction molecule controlling a wide range of cellular responses including contributing to increased malignant behavior of cancer cells.

The identification and functional validation of the kinase as PI 3-K downstream effector molecule underscores the strength of the atugen approach to find novel targets. The use of the company’s proprietary mRNA knockdown technologies (GeneBlocs® antisense molecules, improved synthetic siRNA, vector expression systems for siRNA, ribozymes and superior transfection reagents) together with atugen’s expertise in gene function elucidation has to date resulted in 19 functionally validated cancer targets that act in the PI 3-K pathway.


“We are in the process of out-licensing this novel kinase target to partners,” said Dr. Klaus Giese, atugen’s Chief Scientific Officer and Vice President of Research. “The breakthrough in this complex pathway endorses our approach, which aims at providing our partners and in-house projects with the best targets for therapeutic intervention within a given disease cascade. We have already started to dissect a complementary pathway, the TGF-beta/Smad pathway.”

Caroline Stupnicka | alfa
Further information:
http://www.atugen.de

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

Leipzig HTP-Forum discusses "hydrothermal processes" as a key technology for a biobased economy

12.07.2017 | Event News

 
Latest News

Researchers create new technique for manipulating polarization of terahertz radiation

20.07.2017 | Information Technology

High-tech sensing illuminates concrete stress testing

20.07.2017 | Materials Sciences

First direct observation and measurement of ultra-fast moving vortices in superconductors

20.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>